JP2013538790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538790A5 JP2013538790A5 JP2013519111A JP2013519111A JP2013538790A5 JP 2013538790 A5 JP2013538790 A5 JP 2013538790A5 JP 2013519111 A JP2013519111 A JP 2013519111A JP 2013519111 A JP2013519111 A JP 2013519111A JP 2013538790 A5 JP2013538790 A5 JP 2013538790A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- lymphoma
- seq
- cell
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10169795 | 2010-07-16 | ||
| EP10169795.1 | 2010-07-16 | ||
| EP10175586.6 | 2010-09-07 | ||
| EP10175586 | 2010-09-07 | ||
| PCT/EP2011/062133 WO2012007576A1 (en) | 2010-07-16 | 2011-07-15 | Superior efficacy of cd37 antibodies in cll blood samples |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016148217A Division JP2017019800A (ja) | 2010-07-16 | 2016-07-28 | Ｃｌｌ血液サンプルにおけるｃｄ３７抗体の優れた効果 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013538790A JP2013538790A (ja) | 2013-10-17 |
| JP2013538790A5 true JP2013538790A5 (https=) | 2015-12-24 |
Family
ID=44546328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519111A Pending JP2013538790A (ja) | 2010-07-16 | 2011-07-15 | Ｃｌｌ血液サンプルにおけるｃｄ３７抗体の優れた効果 |
| JP2016148217A Pending JP2017019800A (ja) | 2010-07-16 | 2016-07-28 | Ｃｌｌ血液サンプルにおけるｃｄ３７抗体の優れた効果 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016148217A Pending JP2017019800A (ja) | 2010-07-16 | 2016-07-28 | Ｃｌｌ血液サンプルにおけるｃｄ３７抗体の優れた効果 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20120189618A1 (https=) |
| EP (2) | EP2593479A1 (https=) |
| JP (2) | JP2013538790A (https=) |
| KR (1) | KR20130100918A (https=) |
| CN (2) | CN103003309A (https=) |
| AU (1) | AU2011278227B2 (https=) |
| BR (1) | BR112013001012A2 (https=) |
| CA (1) | CA2799036A1 (https=) |
| CL (1) | CL2013000101A1 (https=) |
| EA (1) | EA025365B1 (https=) |
| IL (1) | IL222775A (https=) |
| MX (1) | MX341463B (https=) |
| NZ (2) | NZ703225A (https=) |
| PH (1) | PH12013500118A1 (https=) |
| WO (1) | WO2012007576A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| WO2013160396A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| JP2015517511A (ja) | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 |
| US10294304B2 (en) | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
| US11578115B2 (en) | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| CN118599009A (zh) | 2017-03-16 | 2024-09-06 | 综合医院公司 | 靶向cd37的嵌合抗原受体 |
| JP7330942B2 (ja) | 2017-03-31 | 2023-08-22 | ジェンマブ ホールディング ビー．ブイ． | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
| WO2019243636A1 (en) | 2018-06-22 | 2019-12-26 | Genmab Holding B.V. | Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof |
| EP3860715A1 (en) | 2018-10-04 | 2021-08-11 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-cd37 antibodies |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| WO2023057583A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 |
| AU2024362226A1 (en) | 2023-10-18 | 2026-03-05 | Debiopharm International S.A. | Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| RU2423381C2 (ru) * | 2005-07-25 | 2011-07-10 | Трабьон Фармасьютикалз, Инк. | Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул |
| US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| JP2010532764A (ja) * | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| PE20140196A1 (es) * | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| RU2531754C2 (ru) * | 2008-04-11 | 2014-10-27 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US | Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством |
| WO2010057047A1 (en) * | 2008-11-13 | 2010-05-20 | Trubion Pharmaceutics, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
-
2011
- 2011-07-14 US US13/182,471 patent/US20120189618A1/en not_active Abandoned
- 2011-07-15 NZ NZ703225A patent/NZ703225A/en not_active IP Right Cessation
- 2011-07-15 CN CN2011800349727A patent/CN103003309A/zh active Pending
- 2011-07-15 CN CN201610095143.4A patent/CN105749276A/zh active Pending
- 2011-07-15 BR BR112013001012A patent/BR112013001012A2/pt not_active IP Right Cessation
- 2011-07-15 NZ NZ603161A patent/NZ603161A/en not_active IP Right Cessation
- 2011-07-15 WO PCT/EP2011/062133 patent/WO2012007576A1/en not_active Ceased
- 2011-07-15 CA CA2799036A patent/CA2799036A1/en not_active Abandoned
- 2011-07-15 EP EP11732464.0A patent/EP2593479A1/en not_active Withdrawn
- 2011-07-15 KR KR1020127032811A patent/KR20130100918A/ko not_active Ceased
- 2011-07-15 AU AU2011278227A patent/AU2011278227B2/en not_active Ceased
- 2011-07-15 JP JP2013519111A patent/JP2013538790A/ja active Pending
- 2011-07-15 EA EA201201660A patent/EA025365B1/ru not_active IP Right Cessation
- 2011-07-15 PH PH1/2013/500118A patent/PH12013500118A1/en unknown
- 2011-07-15 EP EP17174088.9A patent/EP3252077A1/en not_active Withdrawn
- 2011-07-15 MX MX2012013613A patent/MX341463B/es active IP Right Grant
-
2012
- 2012-10-31 IL IL222775A patent/IL222775A/en active IP Right Grant
-
2013
- 2013-01-10 CL CL2013000101A patent/CL2013000101A1/es unknown
- 2013-04-26 US US13/871,345 patent/US20130236454A1/en not_active Abandoned
-
2015
- 2015-04-13 US US14/684,928 patent/US20150266967A1/en not_active Abandoned
-
2016
- 2016-07-28 JP JP2016148217A patent/JP2017019800A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538790A5 (https=) | ||
| Taefehshokr et al. | Promising approaches in cancer immunotherapy | |
| Cerroni et al. | An illustrated guide to skin lymphoma | |
| Luo et al. | Necroptosis-dependent immunogenicity of cisplatin: implications for enhancing the radiation-induced abscopal effect | |
| US20190328838A1 (en) | Compositions comprising il-2 fusion proteins and methods for treating neoplasia | |
| JP7388635B2 (ja) | 免疫チェックポイント阻害薬の有効性判定バイオマーカー | |
| Hollebecque et al. | Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed/refractory non-hodgkin lymphoma | |
| MX2010005099A (es) | Usos de anticuerpos anti-cd40. | |
| CN118834840A (zh) | 嵌合痘病毒组合物及其用途 | |
| PH12015502017A1 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune disease | |
| RU2017117664A (ru) | Комбинация | |
| JP2015517512A5 (https=) | ||
| Wang et al. | Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study | |
| Smith et al. | PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma | |
| PH12013500118A1 (en) | Superior efficacy of cd37 antibodies in cll blood samples | |
| JP2015517511A5 (https=) | ||
| WO2021159035A1 (en) | Oncolytic virus compositions and methods for the treatment of cancer | |
| KR20220116438A (ko) | 암 치료를 위한 미생물총 및 대사산물의 힘 활용 | |
| CN119816313A (zh) | 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法 | |
| Finocchiaro et al. | Hypermutations in gliomas: a potential immunotherapy target | |
| JP2015516980A5 (https=) | ||
| CN110168089A (zh) | 抑制cd39表达的免疫抑制恢复寡核苷酸 | |
| WO2018053270A1 (en) | Modified natural killer cells for the treatment of cancer | |
| CN113766955A (zh) | 对携带her2外显子21插入的癌细胞具有抗肿瘤活性的化合物 | |
| JP2019532635A (ja) | 腫瘍溶解性ウイルスを腫瘍に標的化する方法 |